TBNBiotech
Lipidation and Its Discontents
Publication: AAAS: Keyword search for query
Author: Not available in collected metadata
Source published: 27/10/2026, 03:02:35 UTC
Briefing created: 09/11/2026, 03:55:15 UTC
Based on a feed excerpt; full article content has not been acquired. Source evidence retrieved 27/10/2026, 19:19:30 UTC.
Briefings
A 2026 study by medicinal chemists evaluated the CHAMP technique for lipidating drugs to enhance cell penetration. Using HaloTag-driven assays in E. coli and HeLa cells, researchers found that bacterial membranes act as a substantial barrier, preventing most lipidated compounds from entering the cytosol, whereas mammalian cells show variable success depending on lipid tail length and saturation. The study concludes that lipidation is not a universal solution and warns against relying on it for Gram-negative bacteria.
Key points
- The CHAMP technique uses HaloTag-driven membrane penetration to assess drug delivery, where a chloroalkane azide reacts with a drug's azide group to form a triazole, allowing fluorescence measurement to quantify membrane entry.
- In E. coli, no lipid conjugate accumulated significantly more than the unmodified drug, and only very short alkyl chains (C3-C4) showed any penetration, while longer chains were blocked by the outer membrane barrier.
Context
This research addresses the need for deeper evidence on compound modification rules for increasing cell penetration. It provides specific data on the CHAMP technique's efficacy across different cell types, highlighting the stark difference between bacterial and mammalian membrane barriers.
Limitations
Results are limited to E. coli and HeLa cell lines; no additional background on prior lipidation studies is supplied. The study does not claim causality for all observed trends, and some earlier papers may have measured membrane attachment rather than cytosolic entry.
Generated by Bittrees-hosted qwen35-2b sha256:aaf42c8b7c3c on 09/11/2026, 03:55:15 UTC. Based on publisher-provided feed evidence; may not cover the full original article. Check the source for details.
View archived briefing on IPFS
bafybeiakif7am2d4c4gpodhskelvsmhev7dsun3st475kivck22dcyx77u